Association between Toll-Like Receptor 4 Gene and inflammatory bowel disease among Jordanian patients

Main Article Content

Malek Zihlif
Zainab ZAKARAYA
Rawan NAEL
Abed Al-Rahman AL-SHUDIEFAT
Ahmad : SUNDOOKAH
Ahmad R. ALSAYED

Keywords

IBD, TLR4, genotype, polymorphism, jordan

Abstract

Background: Inflammatory bowel disease (IBD) is a set of chronic inflammatory gastrointestinal disorders that affects many patients worldwide, with a peak incidence in early adult life. The Toll-like receptor 4 (TLR4) binds Lipopolysaccharide (LPS) with the assistance of accessory proteins and activates signal transduction pathways of the innate immune system. TLR4 is significantly up-regulated in the active disease phase of IBD. It has been reported that the two most common single nucleotide polymorphisms (SNPs) of TLR4 (Asp299Gly and Thr399Ile) have been shown to suspend TLR4-mediated LPS signaling in vitro and are associated with endotoxin hyporesponsiveness in human beings. This study aims to determine if there is an association between certain TLR4 (Asp299Gly and Thr399Ile) polymorphisms and IBD in Jordanian patients, to determine the genotype and allele frequencies of TLR4 (Asp299Gly and Thr399Ile) polymorphisms among IBD and healthy Jordanian groups, to determine the association between the age and IBD Jordanian patients. Methods: 96 IBD patients aged between 17-72 years and 96 healthy subjects without genetic kinship related to the disease were enrolled and genotyped by TLR4 (Asp299Gly and Thr399Ile) polymorphisms using the polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) assay methods. Results: There was no significant association between TLR4 (Asp299Gly and Thr399Ile) polymorphisms and IBD compared with healthy subjects among Jordanian subjects. Conclusions: IBD incidence was significantly higher in younger age compared to older age, which could be due to the higher activity of the digestive system in those patients compared to older adults.

Abstract 322 | PDF Downloads 254

References

1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. The Lancet. 2007;369(9573):1627-40.https://doi.org/10.1016/s0140-6736(07)60750-8
2. Kittinger GW, Beamer NB, Hagemenas F, Hill JD, Baughman WL, Ochsner A. Evidence for autonomous pituitary-adrenal function in the near-term fetal rhesus (Macaca mulatta). Endocrinology. 1972;91(4):1037-44. https://doi.org/10.1210/endo-91-4-1037
3. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427-34. https://doi.org/10.1038/nature06005
4. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflammatory bowel diseases. 2010;16(9):1583-97.https://doi.org/10.1002/ibd.21282
5. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(suppl5):v1-v16.
6. Kaser A, Zeissig S. Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573-621. https://doi.org/10.1146/annurev-immunol-030409-101225
7. Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. J Immunol. 2005;174(8):4453-60. https://doi.org/10.4049/jimmunol.174.8.4453
8. Okayama N, Fujimura K, Suehiro Y, Hamanaka Y, Fujiwara M, Matsubara T, et al. Simple genotype analysis of the Asp299Gly polymorphism of the Toll-like receptor-4 gene that is associated with lipopolysaccharide hyporesponsiveness. J Clin Lab Anal. 2002;16(1):56-8. https://doi.org/10.1002/jcla.2075
9. Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis. Gut. 2004;53(7):987-92. https://doi.org/10.1136/gut.2003.030205
10. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269(22):15419-22.
11. Browning BL, Huebner C, Petermann I, Gearry RB, Barclay ML, Shelling AN, et al. Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol. 2007;102(11):2504-12. https://doi.org/10.1111/j.1572-0241.2007.01463.x
12. Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y, et al. Lack of common NOD2 variants in Japanese patients with Crohn’s disease. Gastroenterology. 2002;123(1):86-91. https://doi.org/10.1053/gast.2002.34155
13. Leong RW, Armuzzi A, Ahmad T, Wong ML, Tse P, Jewell DP, et al. NOD2/CARD15 gene polymorphisms and Crohn’s disease in the Chinese population. Aliment Pharmacol Ther. 2003;17(12):1465-70. https://doi.org/10.1046/j.1365-2036.2003.01607.x
14. Wang ZW, Ji F, Teng WJ, Yuan XG, Ye XM. Risk factors and gene polymorphisms of inflammatory bowel disease in population of Zhejiang, China. World J Gastroenterol. 2011;17(1):118-22. https://doi.org/10.3748/wjg.v17.i1.118
15. Xie Z, Lv B, Zou L, Shang X, Zhou Y. Genotyping of toll-like receptor 4 in Hubei population of Chinese. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong. 2004;33:630-2.
16. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007;39(5):596-604.
https://doi.org/10.1038/ng2032
17. Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology. 2007;133(5):1670-89.
18. Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol. 2005;3(1):11-24. https://doi.org/10.1016/s1542-3565(04)00441-0
19. Triester SL, Leighton JA, Leontiadis GI, Fleischer DE, Hara AK, Heigh RI, et al. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with obscure gastrointestinal bleeding. Am J Gastroenterol. 2005;100(11):2407-18. https://doi.org/10.1111/j.1572-0241.2005.00274.x
20. Hong J, Leung E, Fraser AG, Merriman TR, Vishnu P, Krissansen GW. TLR2, TLR4 and TLR9 polymorphisms and Crohn’s disease in a New Zealand Caucasian cohort. J Gastroenterol Hepatol. 2007;22(11):1760-6. https://doi.org/10.1111/j.14401746.2006.04727.x
21. Zouiten-Mekki L, Kharrat M, Karoui S, Serghimi M, Fekih M, Matri S, et al. Tolllike receptor 4 (TLR4) polymorphisms in Tunisian patients with Crohn’s disease: genotype-phenotype correlation. BMC Gastroenterol. 2009;9:62.
https://doi.org/10.1186/1471-230x-9-62
22. Prelipcean CC, Mihai C, Gogalniceanu P, Mihai B. What is the impact of age on adult patients with inflammatory bowel disease? Clujul Med. 2013;86(1):3-9. http://www.ncbi.nlm.nih.gov/pmc/articles/pmc4462481/
23. Chen L, Lin MJ, Zhan LL, Lv XP. Analysis of TLR4 and TLR2 polymorphisms in inflammatory bowel disease in a Guangxi Zhuang population. World J Gastroenterol. 2012;18(46):6856-60. https://doi.org/10.3748/wjg.v18.i46.6856
24. Irving PM, Gearry RB, Sparrow MP, Gibson PR. Review article: appropriate use of corticosteroids in Crohn’s disease. Aliment Pharmacol Ther. 2007;26(3):313-29. https://doi.org/10.1111/j.1365-2036.2007.03379.x

Most read articles by the same author(s)